Literature DB >> 7735581

The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma.

S M Nasser1, M Patel, G S Bell, T H Lee.   

Abstract

Patients with aspirin sensitive asthma (ASA) can be desensitized to aspirin but the mechanisms by which this happens are unknown. To test the hypothesis that there may be a reduction in aspirin-induced leukotriene release following aspirin desensitization, we studied nine patients with ASA, 37 +/- 2.3 yr of age (mean +/- SEM) with a baseline FEV1 of 94 +/- 3.5%. Urinary leukotriene E4 (LTE4) and FEV1 were measured before and after ingestion of a threshold dose of aspirin leading to a 15% decrease in FEV1, and then at intervals following desensitization, when a maintenance dose of 600 mg aspirin was ingested. Prior to desensitization, the maximum decrease in FEV1 following ingestion of a threshold dose of aspirin was 15.3 +/- 3.9%, and urinary LTE4 rose from a baseline value of 235 +/- 79.4 pg/mg creatinine to 1,714 +/- 783 pg/mg creatinine at 3 h. Immediately after acute desensitization, which was performed over several days, 600 mg aspirin provoked a maximum decrease in FEV1 of only 3.3 +/- 2.4%, and urinary LTE4 increased from a baseline of 645 +/- 223 pg/mg creatinine to 1,256 +/- 456 pg/mg creatinine. Following ingestion of 600 mg aspirin for 9 +/- 3.2 mo (n = 5; chronic desensitization), urinary LTE4 rose from a basal level of 432 +/- 127 pg/mg creatinine to 749 +/- 257 pg/mg creatinine at 3 h after 600 mg aspirin, and this was accompanied by a maximum decrease in FEV1 of 7.4 +/- 4.5%. Although there was significantly less aspirin-induced LTE4 excretion after acute desensitization, substantial amounts of LTE4 were still produced without any significant change in lung function.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7735581     DOI: 10.1164/ajrccm.151.5.7735581

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  14 in total

Review 1.  The measurement of leukotrienes in human fluids.

Authors:  J Y Westcott
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Aspirin-induced asthma.

Authors:  L T Vaszar; D D Stevenson
Journal:  Clin Rev Allergy Immunol       Date:  2001-08       Impact factor: 8.667

3.  Biological effects of leukotriene E4 on eosinophils.

Authors:  John W Steinke; Julie Negri; Spencer C Payne; Larry Borish
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2014-03-26       Impact factor: 4.006

Review 4.  Pathogenesis of aspirin-exacerbated respiratory disease.

Authors:  Donald D Stevenson; Bruce L Zuraw
Journal:  Clin Rev Allergy Immunol       Date:  2003-04       Impact factor: 8.667

Review 5.  Aspirin-induced asthma: clinical aspects, pathogenesis and management.

Authors:  Ahmed M Hamad; Amy M Sutcliffe; Alan J Knox
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.

Authors:  Katherine N Cahill; Jillian C Bensko; Joshua A Boyce; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2014-09-11       Impact factor: 10.793

7.  COX-1 mediates IL-33-induced extracellular signal-regulated kinase activation in mast cells: Implications for aspirin sensitivity.

Authors:  Dingxin Pan; Kathleen M Buchheit; Sachin K Samuchiwal; Tao Liu; Haley Cirka; Hannah Raff; Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2018-07-12       Impact factor: 10.793

8.  Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.

Authors:  Tao Liu; Yoshihide Kanaoka; Nora A Barrett; Chunli Feng; Denise Garofalo; Juying Lai; Kathleen Buchheit; Neil Bhattacharya; Tanya M Laidlaw; Howard R Katz; Joshua A Boyce
Journal:  J Immunol       Date:  2015-09-04       Impact factor: 5.422

Review 9.  The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

Authors:  Whitney W Stevens; Elina Jerschow; Alan P Baptist; Larry Borish; John V Bosso; Kathleen M Buchheit; Katherine N Cahill; Paloma Campo; Seong H Cho; Anjeni Keswani; Joshua M Levy; Anil Nanda; Tanya M Laidlaw; Andrew A White
Journal:  J Allergy Clin Immunol       Date:  2020-12-09       Impact factor: 10.793

Review 10.  Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.

Authors:  Esha Sehanobish; Mohammad Asad; Mali Barbi; Steven A Porcelli; Elina Jerschow
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.